- Home
- MED vs YARW Comparison
MED vs YARW Comparison
Compare MED & YARW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MED | YARW |
|---|---|---|
| Founded | 1980 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 133.7M | 114.6M |
| IPO Year | 1996 | 2017 |
Fundamental Metrics
Financial Performance| Metric | MED | YARW |
|---|---|---|
| Price | $11.50 | $18.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $57.00 |
| AVG Volume (30 Days) | 90.5K | ★ 147.7K |
| Earning Date | 11-02-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $934,842,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.22 | $18.24 |
| 52 Week High | $14.06 | $44.28 |
Technical Indicators
Market Signals| Indicator | MED | YARW |
|---|---|---|
| Relative Strength Index (RSI) | 43.76 | 26.97 |
| Support Level | $10.01 | N/A |
| Resistance Level | $12.08 | $32.89 |
| Average True Range (ATR) | 0.31 | 2.48 |
| MACD | -0.07 | -0.53 |
| Stochastic Oscillator | 19.41 | 4.64 |
Price Performance
Historical ComparisonAbout MED MEDIFAST INC
Medifast Inc is a old health and wellness company known for its habit-based and coach-guided lifestyle solution OPTAVIA, which provides people with a simple, yet comprehensive approach to address obesity and support a healthy life. The company provides unparalleled coaching support along with community, tailored nutrition and healthy habits, and empowers people to master their weight loss journey through each stage of life. The company has access to GLP-1 medications where clinically appropriate. The company is focused on offering talent to Lifelong Transformation, Making a Healthy Lifestyle Second Nature.
About YARW Yarrow Bioscience Inc. Common Stock
Yarrow Bioscience Inc is a clinical-stage biopharmaceutical company focused on developing biotherapeutics for autoimmune thyroid diseases. Its flagship product candidate, YB-101 (also known as GenSci098), is a humanized, monoclonal antibody targeting the thyroid-stimulating hormone receptor, which Yarrow plans to develop for the treatment of Graves' disease (GD) and potentially thyroid eye disease (TED). The company has one reportable segment relating to the research and development of its research programs, GD and TED.